03140: Efficacy and Tolerability of Gelatin Tannate (Tasectan®) in Canine parvovirus-infected Dogs

Grant Status: Open

Grant Amount: $21,636
Ran Nivy, DVM; The Koret School of Veterinary Medicine, The Hebrew University of Jerusalem
February 1, 2023 - January 31, 2025


Breed(s): -All Dogs
Research Program Area: Gastrointestinal Disease
Donate to Support this Research Program Area


Canine parvovirus (CPV) infection causes severe enteritis in young dogs, with massive intestinal mucosal damage secondary to infection of replicating enterocytes. The resultant breach in intestinal-blood barrier might lead to endotoxemia and bacterial translocation, which if left untreated, leads to fatality rates approximating 91%. Early supportive treatment improves survival rates up to 96% but involves cost-prohibitive, lengthy, hospitalizations. Even though any young, unvaccinated dog is susceptible to CPV infection, certain breeds, including the Doberman Pinscher, Rottweiler and English Springer Spaniel, appear to be at increased risk of developing severe clinical signs. Treatment modalities are mostly supportive and have remained unchanged over the years. Novel therapies have either proved ineffective or prohibitively expensive, and many are not readily available. A novel, affordable and commercially available treatment modality, which reduces the incidence of bacterial translocation and endotoxemia, shortens hospitalization period, curtails financial expenses, and improves fatality rate is therefore highly sought-after. Investigators hypothesize that the addition of gelatin tannate (Tasectan®) to the conservative treatment of puppies infected with CPV will be safe, decrease gut permeability, and will lead to faster clinical recovery. They aim to investigate whether gelatin tannate (Tasectan®) administration to dogs with CPV infection reduces the incidence of endotoxemia and attenuates the inflammatory response as assessed by measuring serum concentrations of C-reactive protein, TNF-α, IL-2, IL-6 and IL-8. The study will also investigate whether gelatin tannate (Tasectan®) administration to dogs with CPV infection reduces morbidity (as assessed by hospitalization time), severity of clinical signs (i.e., vomiting and diarrhea) and fatality rate. Currently, there is paucity of available treatments to CPV-infected dogs, and gelatin tannate might provide additional treatment modality to this world-wide, common intestinal disease.


None at this time.

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Get Canine Health News:
Please leave this field empty
American Kennel Club Canine Health Foundation, Inc

8051 Arco Corporate Dr.
Suite 300
Raleigh, NC 27617

Tax ID# 13-3813813


© 2021 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.